CSL Behring is committed to saving lives and improving the quality of life for patients with rare and serious diseases worldwide.
Within this section, you can learn about people who are leading happy, healthy lives with a bleeding disorder, and record your family history and track your activities and bleeding episodes.
Our commitment is also reflected in our support of programs and activities for patients with rare diseases including bleeding disorders, primary immune deficiencies and Alpha1-proteinase inhibitor deficiencies.
We collaborate with patient advocacy platforms, both disease-specific and umbrella organizations, to promote quality medical care and services and to improve and expand educational and outreach efforts. Through these partnerships we strive to raise public awareness and to enhance appropriate public policies for rare diseases.
We work with government authorities to ensure patients have access to care while also funding medical research.
Finally, as a global company, our public policies extend internationally. Through our membership in the Plasma Protein Therapeutics Association (PPTA), CSL Behring is working with other international trade associations to promote the availability of and access to safe and effective plasma protein therapeutics for all patients.
Examples of Patient Programs
International Rare Disease Day: CSL Behring supports this internationally recognized day established to raise awareness of rare diseases and their impact on patients’ lives by policy makers and the public at large. Rare Disease Day reinforces the importance of rare diseases as a public health priority.
European Organization for Rare Diseases (EURORDIS): CSL Behring partners with EURORDIS, a patient-driven alliance of patient organizations and individuals active in the field of rare diseases. Recently, we awarded EURORDIS a three-year educational grant for the development of a new European rare diseases policy project. This project is the first European initiative designed to collect patient opinions on rare disease policies, intended to build consensus on preferred public health policy scenarios.
LEAD Program: In the U.S., the Local Empowerment for Advocacy Development (LEAD) Program allows CSL Behring to partner with local patient organizations. CSL Behring believes that successful advocacy results from the empowerment of those that are impacted by a particular issue.
Raise Your Voice! Program: This U.S. program supports youth advocacy training programs administered by local patient advocacy organizations. The training program introduces youths aged 16 to 23 years to advocacy.
Last Updated:
3/1/2010 2:17 PM